41138-69-6

Basic information

• Product Name: METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE
• Synonyms: METHYL-7-(3-(R)-T-BUTYL DIMETHYLSILOXY-5-OXO-CYCLOPENT-1-ENYL)-HEPTANOATE;METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE;methyl (R)-(+)-3-(T-bu-dimethylsilyloxy)-5-oxo-1-;METHYL (R)-(+)-3-(T-BU-DIMETHYLSILYLOXY&;(R)-Methyl 7-(3-((tert-butyldimethylsilyl)-oxy)-5-oxocyclopent-1-en-1-yl)heptanoate;1-Cyclopentene-1-heptanoic acid,3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-oxo,methyl ester,(3R)-
• CAS NO: 41138-69-6
• Molecular Formula: C₁₉H₃₄O₄Si
• Molecular Weight: 354.56
• Mol File: 41138-69-6.mol

Chemical Properties

• Boiling Point: 210 °C(lit.)
• Flash Point: 41 °C
• Appearance: /
• Density: 0.977 g/mL at 25 °C(lit.)
• Vapor Pressure: 8.89E-07mmHg at 25°C
• Refractive Index: n20/D 1.467(lit.)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE(41138-69-6)
• EPA Substance Registry System: METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE(41138-69-6)

Safety Data

• Statements: 10
• Safety Statements: 16
• RIDADR: UN 3272 3/PG 3
• Hazardous Substances Data: 41138-69-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it suitable for the development of new drugs and the modification of existing ones.
Used in Fragrance Industry:
METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE is used as a key intermediate in the production of fragrances. Its cyclopentene ring and heptanoate group contribute to the creation of unique and complex scents.
Used in Fine Chemicals Industry:
METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE is used as a versatile intermediate in the synthesis of fine chemicals. Its stability and reactivity make it an ideal candidate for the development of high-quality specialty chemicals.
Used in Organic Chemistry Research:
METHYL (R)-(+)-3-(TERT-BUTYLDIMETHYLSILYLOXY)-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE is used as a valuable tool in the field of organic chemistry for the synthesis and modification of complex molecules. Its unique properties allow researchers to explore new chemical reactions and develop innovative synthetic pathways.

InChI:InChI=1/C19H34O4Si/c1-19(2,3)24(5,6)23-16-13-15(17(20)14-16)11-9-7-8-10-12-18(21)22-4/h13,16H,7-12,14H2,1-6H3/t16-/m0/s1

Upstream product

• 288-32-4 1H-imidazole 
• 1000-50-6 butyldimethylsilyl chloride 
• 41138-61-8 (4R)-4-hydroxy-2-(6-methoxycarbonylhexyl)cyclopent-2-enone 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 60176-77-4 (1S,4R)-4-hydroxy-2-cyclopentenyl acetate 
• 108-22-5 Isopropenyl acetate 
• 61305-35-9 (R)-4-((tert-butyldimethylsilyl)oxy)cyclopent-2-enone 
• 127126-27-6 methyl 7-<3(R)-(acetyloxy)-5-oxo-1-cyclopenten-1-yl>heptanoate 
• 40098-26-8 methyl 7-(3-hydroxy-5-oxocyclopent-1-en-1-yl)heptanoate 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 131392-85-3 C₇H₁₃IO₂Zn 
• 117254-03-2 (3S,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-3-methoxy-2-methylene-cyclopentanone 
• 1745-17-1 methyl hept-6-enoate 
• 150686-70-7 (R)-4-((tert-butyldimethylsilyl)oxy)-2-iodocyclopent-2-en-1-one 

Downstream Products

• 148436-63-9 AH 13205 
• 951401-90-4 C₃₁H₅₀O₇S 
• 951401-89-1 C₃₀H₄₈O₅ 
• 909528-65-0 C₂₅H₃₈O₄ 
• 1369916-94-8 (11R,12R,13E,15S)-11,15-dihydroxy-16-(3-methoxymethylphenyl)-17,18,19,20-tetranorprost-8,13-dienoic acid 
• 1369917-19-0 C₂₅H₃₆O₅ 
• 1369917-14-5 (11R,12R,13E,15S)-9-[(trifluoromethyl)sulfonyloxy]-11,15-bis(tertbutyldimethylsilyloxy)-16-(3-methoxymethylphenyl)-17,18,19,20-tetranorprost-8,13-dienoic acid methyl ester 
• 951401-85-7 C₃₇H₆₆O₅Si₂ 
• 76817-55-5 (8R,11R,12R,15S,16S)-11,15-diydroxy-16-methyl-16-methoxy-9-oxo-prost-13-en-1-oic acid methyl ester 
• 76822-56-5 mexiprostil 
• 3434-33-1 prostaglandin E₁ methyl ester 
• 251292-78-1 7-{(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-(tert-butyl-diphenyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-diphenyl-silanyloxy)-oct-1-enyl]-cyclopentyl}-heptanoic acid methyl ester 

Relevant articles and documents

USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME

The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other drugs, and also to a novel method for the synthesis of mexipros

AROMATIC C 16?-C 20?-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS

The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: wherein R1, R2, R3, R4, X, Y, and Z are defined below. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using theses compounds or the compositions containing them.

Total synthesis of isoprostanes via the two-component coupling process

A short total synthesis of isoprostanes has been achieved using a two-component coupling process combined with a diastereoselective protonation under reagent control. The F1-isoprostanes were easily obtained by stereoselective reduction of the C-9 keto group.

Design and synthesis of 13,14-dihydro prostaglandin F(1α) analogues as potent and selective ligands for the human FP receptor

The in vitro evaluation of a new class of potential bone anabolic agents for the treatment of osteoporosis is described. These compounds are potent and selective ligands for the human prostaglandin F receptor (hFP receptor). The compounds lack the olefin unsaturation required for potency in the natural ligand PGF(2α) yet retain binding affinity for the hFP receptor in the nanomolar to micromolar range. Removal of the alkenes also results in a better selectivity ratio for the hFP receptor over the other prostaglandin receptors tested. A rationale for the selectivity differences of various analogues, based on ligand docking experiments to a putative hFP receptor model, is also described.

Synthesis and antiviral activity of prostaglandin-J1 methyl ester

A prostagIandin-F, a methyl ester derivative (12) possessing three different protecting groups on the hydroxy units was prepared so as to allow selective removal of the group attached to the 11-OH group. Compound (12) was converted into prostaglandin-J, m

Towards a Large Scale Preparation of Mexiprostil

The enantioselective synthesis of mexiprostil (16R-16-methoxy-16-methyl PGE1 methyl ester) is described.The assembly of the prostaglandin framework has been accomplished by the three component coupling process, via consecutive linking of the ω

Novel process and intermediates

This invention relates to the novel processes for the preparation of a 16-methoxy-16-methyl prostaglandin E1 derivative and to the novel intermediates useful therefor.

A highly practical synthesis of natural PGE1,Δ2-trans-PGE1 and 2,2,3,3-tetradehydro-PGE1 via two-component coupling process using zinc-copper reagents

A highly practical synthesis of natural PGE1,Δ2-trans-PGE1 and 2,2,3,3-tetradehydro-PGE1 has been achieved in which the 1,4-addition reaction of the corresponding functionalized zinc-copper reagents to the enones 2 and/or 4 plays a key role.